Among girls, puberty generally begins between the ages of 10 and 14. Boys undergo these changes later, usually between 12 to 16 years of age. Precocious puberty is diagnosed in girls when sexual development begins before the age of 8; in boys, it is diagnosed when these changes occur before age 9. Recently, medical research has linked vitamin D deficiency to a number of diseases, including cancer, obesity and autoimmune disease. …
BPA is a synthetic estrogen that is used to add flexibility to many common products, including food cans and containers, compact discs, eyeglasses, and even baby bottles. It is universally prevalent, and tests indicate that almost everyone has measurable levels of the chemical in their bodies. The chemical has received a great deal of media attention in recent years because of its potential to increase the risk of disease…
The physician scientists sought to identify glioblastoma subtype-specific cancer stem cells. Genetic analyses have shown that high-grade gliomas can be divided into four subtypes: proneural, neural, classic and mesenchymal…
A ruling by the Supreme Court that human genes can't be patented is expected to increase access and drop the cost for tests for gene mutations that greatly raise the risk of developing breast or ovarian cancer. In a bit of a mixed message, the court unanimously decided that certain types of gene tests may still be protected by patents, yet it struck down patents that a company has long held for BRCA genes. The company makes the only test for two of those breast cancer genes, BRCA1 and BRCA2. “It appears that it will allow the market to open up so that other laboratories can offer the test,” said Rebecca Nagy, a genetics counselor at Ohio State University and president of the National Society of Genetic Counselors. And that should make the tests cheaper and available to more women, she said. Hours after the ruling, one company - DNATraits, part of Houston-based Gene By Gene, Ltd. - said it would offer BRCA gene testing in the United States for $995 - less than a third of the current price. A primer on the case: Q: What did the court say? …
Precisely what causes breast cancer recurrence has been poorly understood. But now a piece of the puzzle has fallen into place: Researchers at the Perelman School of Medicine, University of Pennsylvania have identified a key molecular player in recurrent breast cancer — a finding that suggests potential new therapeutic strategies. The study, performed in the laboratory of Lewis A. …
Forget abandoning carbohydrates or detoxing. The new dieting craze sweeping Britain and taking off in the United States lets people eat whatever they like - but only five days a week. “The Fast Diet”, also known as the 5:2 diet, is the brainchild of TV medical journalist Michael Mosley and journalist Mimi Spencer and allows people to eat what they want for five days but only eat 600 calories a day on the other two. Their book, “The Fast Diet”, has topped bestselling book lists in Britain and the United States this year and been reprinted more than a dozen times. Mosley said the diet is based on work by British and U.S. scientists who found intermittent fasting helped people lose more fat, increase insulin sensitivity and cut cholesterol which should mean reduced risk of heart disease and diabetes. He tried this eating regime for a BBC television science programme called “Eat, Fast, Live Longer” last August after finding out his cholesterol level was too high and his blood sugar in the diabetic range. He was stunned by the results. “I started doing intermittent fasting a year ago, lost 8 kgs (18 pounds) of fat over 3 months and my blood results went back to normal,” Mosley told Reuters. Mosley said he had been amazed at the way the diet had taken off with a list of websites set up by followers of the 5:2 diet or variations of the eating regime to share their experiences. Following the success of “The Fast Diet”, Spencer joined forces with dietitian Sarah Schenker to bring out “The Fast Diet Recipe Book” in April which has topped amazon.co.uk's food and drink list with 150 recipes containing under 300 calories. Eating a 600 calorie daily diet - about a quarter of a normal healthy adult's intake - could consist of two eggs for breakfast, grilled chicken and lettuce for lunch, and fish with rice noodles for dinner with nothing to drink but water, black coffee or tea. One day at a time Mosley put the diet's success down to the fact it is psychologically attractive and leads to steady drop in weight with an average weekly loss of 1 pound (0.46kg) for women and slightly more for men. “The problem with standard diets is that you feel like you are constantly having to exercise restraint and that means you are thinking about food all the time, which becomes self-defeating,” said Mosley. “On this regime you are only really on a diet two days a week. It is also extremely flexible and simple.” Britain's National Health Service (NHS) initially expressed doubts about the diet and its long-term effects, saying side effects could include sleeping difficulties, bad breath, irritability, anxiety, and daytime sleepiness. But as the popularity of the 5:2 diet has grown and become one of the most searched diets on the Internet, the NHS has started to look again at the diet and its effects. On its website last month the NHS said the British Dietetic Association (BDA) reviewed a 2011 study by researchers at the UK's University Hospital of South Manchester that suggested intermittent fasting could help lower the risk of certain obesity-related cancers such as breast cancer. “The increasing popularity of the 5:2 diet should lead to further research of this kind,” the BDA said in a statement. Schenker, a sports and media dietitian who works with football clubs and food companies, said it was a shame that the NHS had criticized the eating regime that had proved such a success with so many people. “We are in the midst of an obesity crisis and you need to balance up which is worse - intermittent fasting of staying obese?” Schenker told Reuters. Despite concerns raised by the NHS, the 5:2 diet has been widely praised by those who follow it. Deb Thomas, 50, a management coach from London, said she has followed the diet for six months and dropped a couple of dress sizes. This has also inspired her husband to join her in fasting two days a week. “It is such an easy diet to follow that fits into my way of life,” Thomas said. “You have a tough day of not eating but you know the next day you can eat normally again, and that keeps you going.”source : http://www.foxnews.com/health/2013/06/13/new-diet-craze-offers-five-days-feasting-for-two-days-famine/
Global drugmakers said on Wednesday they would cooperate with an independent review to address concerns of a potential link between widely used diabetes medicines and pancreatic cancer and other safety problems. The American Diabetes Association (ADA) this week called for a new evaluation of clinical data on drugs used to control blood sugar for patients with type 2 diabetes. They include Merck & Co's $4 billion a year Januvia franchise, Novo Nordisk's Victoza, and Byetta and Onglyza from Bristol-Myers Squibb Co and AstraZeneca Plc, among others. “People who are taking these medications, or who may consider taking them, should have the benefit of all that is currently known about their risks and advantages in order to make the best possible decisions about their treatment,” Dr. Robert Ratner, ADA's chief scientific and medical officer, said in a statement. The medicines are called incretin mimetics because they mimic hormones the body produces to stimulate release of insulin, and are from classes of drugs known as GLP-1 receptor agonists and DPP-4 inhibitors. GLP-1 drugs boost insulin production by the pancreas and slow absorption of food. DPP-4 inhibitors block an enzyme the breaks down the GLP-1 peptide in the gut, thereby increasing insulin production. The U.S. Food and Drug Administration in March said it was studying unconfirmed reports that the drugs cause inflammation of the pancreas and pre-cancerous changes to cells in the pancreas. European health regulators are also studying the issue. Around the same time, new concerns arose from a small study conducted by a leading diabetes expert, Dr. Peter Butler, from the University of California, Los Angeles. Butler examined human pancreases from patients who had died of causes unrelated to pancreatic disease and found more pancreas lesions and one cancerous tumor in those who had taken Januvia or Byetta compared with nondiabetics or diabetics who had not taken those medicines. More than 370 million people are living with diabetes worldwide, with type 2 accounting for 90 percent to 95 percent of the cases, according to the International Diabetes Federation. Without significant lifestyle changes to curb obesity and other causes of diabetes, that number could balloon to as many as 552 million by 2030, the organization projected. NO FIRM EVIDENCE OF RISK Bristol-Myers and AstraZeneca issued a joint statement expressing support for the ADA initiative. Merck said it is committed to participating in the ADA effort, and is separately conducting a 14,000-patient heart safety study of Januvia. Danish drugmaker Novo Nordisk, in an emailed comment, said its studies to assess safety signals of its $1.8 billion a year Victoza do not reveal any evidence of increased risk of pancreatitis or pancreatic cancer. “As far as the ADA proposal is concerned, this is something that I do support from a conceptual basis,” said Alan Moses, Novo's global chief medical officer, in a telephone interview. “In principle, Novo Nordisk absolutely supports working with the other companies, but the final details depend on what specifically is being proposed,” Moses said, adding “it all depends on the credibility of the data that's being evaluated.” The safety concerns are being discussed on Wednesday and Thursday at a workshop conducted by the National Institutes of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). A document outlining the FDA's presentation at the workshop was handed out at the meeting. Attendees quoted it as saying the agency review of trial data on the drugs did not provide enough evidence to say whether there is a link to pancreatitis, and that long-term study would be required to determine any cancer risk. A FDA spokeswoman could not immediately confirm the contents of the document. “The FDA basically appears to just be saying 'look, there just isn't enough information here to make an informed decision',” said Mark Schoenebaum, a drug industry analyst with ISI Group who was attending to two-day NIH/NIDDK workshop. “There are no conclusions at this point in time from the meeting and I doubt very much there will be because the science quite frankly is immature about the whole area of pancreatic cancer,” said Novo's Moses, who will address the workshop on Thursday. “Everybody agrees that this is an incredibly complex area.” In an interview with Reuters earlier this week Peter Stein, Merck vice president of clinical research for diabetes, expressed full confidence in the safety of Januvia. During the workshop, Merck said it will present data on the safety profile of Januvia, known chemically as sitagliptin, including an updated analysis of data from more than 14,000 patients from 25 randomized clinical trials. Merck last month reported a surprising decline in first quarter sales of Januvia, which has been the drugmaker's fastest growing medicine since its 2006 approval. It was not clear if increased competition, safety concerns or other factors led to the 4 percent slip in quarterly sales to $884 million.source : http://www.foxnews.com/health/2013/06/13/drugmakers-to-cooperate-in-safety-review-diabetes-drugs/
Doctors have long recommended exercise to reduce the risk of type 2 diabetes, especially in those at high risk for the condition. But a new study found that doing a short walk right after you eat may be the simplest and most effective strategy, especially for older adults. The study,  published in Diabetes Care, found that a 15-minute walk about a half an hour after each meal was as effective at reducing blood sugar as a single 45-minute morning or late afternoon walk.  But researchers found that the quick walk after dinner was even more effective than the longer afternoon walk in lowering blood sugars (glucose) over night into the next day. “The post-meal exercise was especially efficient at lowering the 3-hour post-dinner blood sugar glucose,” said the study’s lead author Dr. Loretta DiPietro, chair of the department of exercise science at George Washington University School of Public Health and Health Services. The study also found that the most effective time to go for a post-meal walk was after the evening meal. Dinner is usually the largest meal of the day, causing the greatest rise in blood sugar, which lasts into the night and the next morning. These affects were significantly reduced by the after dinner walk.    This is an important finding for older people. As you age, your insulin response to help shuttle sugar out of the bloodstream becomes sluggish. Insulin levels also start to fall in the afternoon and into the evening, adding to the weaker response to sugars you consume. Many people end up sitting around after dinner and going to bed with very high blood sugar levels – which according to DiPietro – is the worst thing you can do. When you exercise, contracting muscles help to clear sugar from the blood and get it stored in the muscles or liver. In this study, older adults walked at a moderate pace, not a brisk walk and not a leisurely stroll. This study, though small, was one of the first to look at the timing of exercise. The general recommendations are to get 150 minutes of exercise a week or at least 30 minutes five days a week. But the study looked at what happened a half an hour after a meal, during the time when sugar begins to flood the blood stream. “When you look at the data, you can see the blood sugar started to go up after a meal, and the exercise abruptly halted that upward rise in blood sugar,” said DiPietro. Though the findings need to be confirmed in larger trials, they are important for those with prediabetes and older individuals. An estimated 79 million Americans have prediabetes but most have no idea they are even at risk. “It may be easy for older adults to take a short walk or combine walking after a meal with running errands or walking the dog,” said DiPietro. The findings may be important for others including pregnant women who are at risk of gestational diabetes.  And if you overindulged in a meal, going for a brisk walk may help your body get rid of that excess sugar more efficiently.Laurie Tarkan is an award-winning health journalist whose work appears in the New York Times, among other national magazines and websites. She has authored several health books, including “Perfect Hormone Balance for Fertility.” Follow her on Twitter and Facebook.source : http://www.foxnews.com/health/2013/06/12/walking-after-meals-may-reduce-diabetes-risk/
Researchers from the Department of Public Health at the University of Oxford sought evidence of a decline in population-based breast cancer mortality that could be attributed to the implementation of mammographic screening programmes. They concluded that population-based mortality statistics for England do not show a past benefit of breast cancer screening…
Health officials say diabetes-related deaths in New York City have hit a record high, though the death rate is below the national average. The city Health Department said Monday that the disease was the underlying or a contributing cause of 5,695 deaths in 2011. That is about 160 more such deaths than in 2010 and 1,260 more than in 1990. That happened while the city's overall death rate hit an all-time low in 2010, when almost 8,000 fewer people died than in 2000. The city's diabetes death rate now amounts to 67 fatalities per 100,000 people. The federal Health and Human Services Department says the national rate was just over 73 diabetes-related deaths per 100,000 people in 2007. The city is launching a radio ad campaign about the risks of diabetes.source : http://www.foxnews.com/health/2013/06/11/diabetes-related-deaths-in-new-york-city-hit-all-time-high/